drugset / Trial / NCT06231680
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Phase 2
Unknown
132 enrolled
Henan Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore the dose and safety of thalidomide for the prevention and treatment of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP)
Timeline
- Start
- 2024-01-19
- Primary completion
- 2024-06-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 50 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |
| Background | Albumin-Bound Paclitaxel | Unknown | — | — |
| Background | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Lobaplatin | Small molecule | — | — |
| Background | Nedaplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |